Research programme: RNA targeted therapeutics - Translate Bio

Drug Profile

Research programme: RNA targeted therapeutics - Translate Bio

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RaNA Therapeutics
  • Developer Shire; Translate Bio
  • Class Oligonucleotides
  • Mechanism of Action RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis; Friedreich's ataxia; Inborn urea cycle disorders; Spinal muscular atrophy
  • Research Inflammation; Musculoskeletal disorders

Most Recent Events

  • 27 Jun 2017 RaNA Therapeutics is now called Translate Bio
  • 27 Jun 2017 Translate Bio announces intention to file IND to the US FDA for Cystic fibrosis and Inborn urea cycle disorders by the end of 2017
  • 27 Jun 2017 Translate Bio plans a phase I trial in Cystic fibrosis in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top